Patents Issued in August 4, 2020
-
Patent number: 10729775Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: GrantFiled: June 28, 2018Date of Patent: August 4, 2020Assignee: NOVARTIS AGInventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura Ellen West, Thomas Zabawa, Junping Zhao
-
Patent number: 10729776Abstract: A composition includes a plurality of coacervate micro and/or nanodroplets of oxidized alginate and a methacrylated gelatin.Type: GrantFiled: October 9, 2018Date of Patent: August 4, 2020Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Eben Alsberg, Oju Jeon, David Wolfson
-
Patent number: 10729777Abstract: A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.Type: GrantFiled: April 10, 2018Date of Patent: August 4, 2020Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Bradley T. Lang, Jared M. Cregg, Jerry Silver, Yi-Lan Weng
-
Patent number: 10729778Abstract: Prodrugs or a pharmaceutically acceptable salt thereof which comprise a covalent treprostinil carrier conjugate, as well as their pharmaceutical composition, may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).Type: GrantFiled: January 27, 2017Date of Patent: August 4, 2020Assignee: Ascendis Pharma A/SInventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogøe, Thomas Wegge, Oliver Keil, Joachim Zettler
-
Patent number: 10729779Abstract: The present invention provides a composition having an antifungal activity without depending on conventional compositions having anticandidal activity or combinations of such compositions. The composition comprises a complex of lysozyme bonded to chitosan. The composition according to the present invention is applicable to candidiasis of the skin and mucous membranes, in particular, oral candidiasis and vagina candidiasis affecting a large number of patients and can ameliorate the symptoms of these diseases, heal the same and prevent infection of the same. The composition comprises a complex of lysozyme, which has been widely used as a highly safe natural food additive, with a polysaccharide and, therefore, can reassure patients who use the same and ease their burden. The composition according to the present invention comprises a complex of lysozyme, which is a highly safe natural food additive, with a polysaccharide and, therefore, can be safely used by patients without considering any risk.Type: GrantFiled: August 31, 2016Date of Patent: August 4, 2020Assignees: Wako Filter Technology Co., Ltd., Teikyo UniversityInventors: Hiroki Kageshima, Akira Saito, Yoichi Murakami, Shigeru Abe, Kazumi Hayama, Miki Takahashi, Miho Abe
-
Patent number: 10729780Abstract: The present invention provides methods for preparation of stable multivalent pneumococcal polysaccharide-protein conjugate vaccine formulations. Instant stable formulations show optimal percent adsorption for each conjugate wherein, aggregation can be prevented by employing i) Individual or separate adsorption for conjugates that otherwise show lower percent adsorption by combined adsorption ii) Histidine-Succinic acid buffer system along with shift in pH from neutral pH to acidic pH iii) a polysaccharide to protein ratio between 0.5 to about 1.4 iv) a six-bladed Rushton type turbine impeller in formulation vessels.Type: GrantFiled: June 3, 2016Date of Patent: August 4, 2020Assignee: Serum Institute of India Private Ltd.Inventors: Rajeev Mhalasakant Dhere, Hitesh Kumar Malviya, Swapan Kumar Jana, Sambhaji Shankar Pisal, Asha Dinesh Mallya, Sunil Mahor, Manish Maheshkumar Gautam, Chetan Vilas Joshi, Venkata Vamsi Krishna Malepati, Prashant Shivaji Jadhav
-
Patent number: 10729781Abstract: Isolated or recombinant anti-LGR4 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.Type: GrantFiled: December 9, 2016Date of Patent: August 4, 2020Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Qingyun Liu, Xing Gong, Kendra Carmon
-
Patent number: 10729782Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- or -L1-L2-LP- wherein the antibody is connected to the terminal of L1, the antitumor compound is connected to the terminal of Lc or LP, and any one or two or more of linkers of L1, L2, and LP has a hydrophilic structure.Type: GrantFiled: November 22, 2017Date of Patent: August 4, 2020Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Takeshi Masuda, Hideki Miyazaki, Yuji Kasuya, Yuki Abe, Yusuke Ogitani
-
Patent number: 10729783Abstract: The present invention relates to hollow silica nanoparticles as a drug delivery system loading bioactive ingredients. Particularly, the present invention relates to silica nanoparticles comprising multi-layered silica shells with one or more bioactive ingredients encapsulated within and their applications in drug delivery; and processes of preparing the same.Type: GrantFiled: August 18, 2017Date of Patent: August 4, 2020Assignee: NATIONAL TAIWAN UNIVERSITYInventors: Chung-Yuan Mou, Nai-Yuan Kou, Si-Han Wu, Yi-Ping Chen
-
Patent number: 10729784Abstract: The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.Type: GrantFiled: January 11, 2019Date of Patent: August 4, 2020Assignees: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSM, BIONTECH RNA PHARMACEUTICALS GMBHInventors: Ugur Sahin, Tim Beissert, Marco Poleganov, Stephanie Herz, Lars Koste
-
Patent number: 10729785Abstract: The present invention relates to particles comprising protamine, RNA and at least one endosome destabilizing agent, to methods of their production and to pharmaceutical compositions or kits containing the particles. It further relates to particles comprising protamine and RNA for use in methods of treatment or prevention of diseases and to kits comprising such particles together with at least one endosome destabilizing agent.Type: GrantFiled: May 19, 2014Date of Patent: August 4, 2020Assignee: BioNTech SEInventor: Steve Pascolo
-
Patent number: 10729786Abstract: Nanoparticles gene carriers, particularly nanoparticle gene carriers which exhibit increased rates of diffusion through cystic fibrosis (CF) mucus, as well as methods of making and using thereof, are described herein. The nanoparticle gene carriers are formed from a nucleic acid complexed to one or more biocompatible, polycationic polymers. The nanoparticle gene carriers also contain one or more mucus resistant polymers. In a particular preferred embodiment, the nanoparticle gene carrier is a nanoparticle formed from one or more nucleic acids, PEI, and a mucus-resistant/diffusive graft copolymer composed of a PEI backbone functionalize by one or more PEG side chains. The nanoparticle gene carriers can efficiently diffuse through CF mucus, and can effectively serve as a vehicle to administer one or more nucleic acids to a patient suffering from CF.Type: GrantFiled: May 11, 2017Date of Patent: August 4, 2020Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Jung Soo Suk, Justin Scot Hanes
-
Patent number: 10729787Abstract: The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduced to a subject by systemic administration. Specifically, the invention relates to methods comprising the in vivo delivery of short interfering nucleic acid (siNA) molecules that target a myostatin gene expressed by a subject, wherein the siNA molecule is conjugated to a lipophilic moiety, such as cholesterol. The myostatin siNA conjugates that are delivered as per the methods disclosed are useful to modulate the in vivo expression of myostatin, increase muscle mass and/or enhance muscle performance. Use of the disclosed methods is further indicated for treating musculoskeletal diseases or disorders and/or diseases or disorders that result in conditions in which muscle is adversely affected.Type: GrantFiled: May 31, 2018Date of Patent: August 4, 2020Assignee: SIRNA THERAPEUTICS, INC.Inventors: Marija Tadin-strapps, Tayeba Khan, Walter Richard Strapps, Laura Sepp-Lorenzino, Vasant R. Jadhav, Duncan Brown
-
Patent number: 10729788Abstract: In alternative embodiments, provided are methods for increasing levels of and/or upregulating the expression of ApoA-I Binding Protein (APOA1BP, AIBP, or AI-BP) to treat, ameliorate, prevent, reverse, decrease the severity or duration of: a neuropathic pain, including an inflammation-induced neuropathic pain, a nerve or CNS inflammation, a, a post nerve injury pain, a post-surgical pain, a chemotherapeutic-induced peripheral neuropathy (CIPN) (e.g., cisplatin-induced allodynia) a neurodegeneration or neurodegenerative disease or condition, a migraine, and/or a hyperalgesia.Type: GrantFiled: December 5, 2016Date of Patent: August 4, 2020Assignee: The Regents of the University of CaliforniaInventors: Yury Miller, Tony L. Yaksh
-
Patent number: 10729789Abstract: The present application discloses a recombinant AAV vector comprising a promoter that targets gene expression to myofibroblast-like lineage of cells in the heart. The present application, also discloses the preparation and use of AAV expression cassettes using a modified periostin promoter that successfully drives gene expression in cardiac myofibroblast-like cells. The present invention encompasses compositions and methods useful for treating myocardial infarction. Further comprising compositions and methods for preparing and using AAV vectors for targeting cells and inducing gene expression. The compositions and methods of the invention are useful for efficiently targeting cardiac myofibroblasts following a cardiac injury, disease, or disorder. Further comprising a kit for effecting alleviation of the various diseases or disorders recited herein.Type: GrantFiled: March 1, 2017Date of Patent: August 4, 2020Assignee: University of Virginia Patent FoundationInventor: Brent A. French
-
Patent number: 10729790Abstract: The present disclosure relates to nucleic acid promoter sequences that are able to specifically express genes operatively linked to the promoter in brainstem and spinal motor neuron cells, and to methods for using such promoters to selectively express genes in motor neurons in vitro and in vivo. It is based, at least in part, on the discovery that the nucleic acid of SEQ ID NO: 1 functioned as a motor neuron-specific promoter and was successful in expressing transgenes in motor neuron cells in vivo. The present disclosure also relates to compositions that can increase the activity or expression level of miR-218 and to compositions that can decrease the expression of miR-218 target nucleic acids.Type: GrantFiled: May 24, 2016Date of Patent: August 4, 2020Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIESInventor: Neal Dilip Amin
-
Patent number: 10729791Abstract: The application relates to methods for determining a parameter such as toxicity and pharmacokinetic behavior for a pharmaceutical compound against a disease or disorder. The test animals being used are non-human animals not suffering from or is not showing symptoms or signs of the disorder and which do not provoke an immune response against said pharmaceutical compound. These animals are obtainable by administration of a peptide comprising an oxidoreductase motif further comprising an NKT peptide epitope or an MHC class II T cell epitope of said pharmaceutical compound, wherein said motif and said epitope are separated by a linker of between 0 and 4 amino acids.Type: GrantFiled: May 11, 2016Date of Patent: August 4, 2020Assignee: IMCYSE SAInventors: Jean-Marie Saint-Remy, Luc Vander Elst, Vincent Carlier
-
Patent number: 10729792Abstract: There is provided herein, a texaphyrin-phospholipid conjugate, wherein the texaphyrin-phospholipid conjugate comprises a texaphyrin, texaphyrin derivative or texaphyrin analog covalently attached to a lipid side chain of a phospholipid.Type: GrantFiled: April 14, 2016Date of Patent: August 4, 2020Assignee: UNIVERSITY HEALTH NETWORKInventors: Gang Zheng, Joseph Keca
-
Patent number: 10729793Abstract: The invention relates to a method of imaging arthritis in a subject, comprising administering to the subject a tracer which comprises a peptide conjugated to a radionuclide, and imaging the subject by 2D nuclear imaging or by 3D detection of single-photon emission events.Type: GrantFiled: June 23, 2016Date of Patent: August 4, 2020Assignee: GUY'S AND ST. THOMAS' HOSPITAL NHS FOUNDATION TRUSTInventor: Toby Garrood
-
Patent number: 10729794Abstract: The invention provides a method for the purification of 227 Th from a mixture comprising 227 Th and 223 Ra, said method comprising: i) preparing a first solution comprising a mixture of 227 Th and 223 Ra ions dissolved in a first aqueous buffer; ii) loading said first solution onto a separation material such as a strong cation exchange resin; iii) eluting 227 Th from the separation material, whereby to generate a second solution comprising 227 Th; iv) Optionally rinsing said separation material using a first aqueous washing medium; The invention additionally provides a method for forming a radio pharmaceutical comprising complexing the purified 227 Th, the pharmaceutical product and its use in treatment of disease such as cancer and a kit for generation of such a product.Type: GrantFiled: December 29, 2016Date of Patent: August 4, 2020Assignee: BAYER ASInventors: Janne Olsen Frenvik, Olav B. Ryan
-
Patent number: 10729795Abstract: A method for sterilizing a concentrated composition and a diluent. The diluent is contained in a large container, and the concentrated composition is contained in a small container that is positioned within the large container. The combined containers are placed in at least one sealing layer that is hermetically sealed, and is also preferably placed in a second sealing layer that is also hermetically sealed. The bagged container is then placed in a carton, which preferably has a liner, and the carton is closed. The carton is then irradiation sterilized. The carton is delivered to the clean room. At a first staging area, the carton is opened and the bagged container is removed and brought to a second staging area. At the second staging area, the second sealing layer is removed and the container can be stored in the first sealing layer. The container is brought into the clean environment, where the first sealing layer is removed.Type: GrantFiled: January 12, 2004Date of Patent: August 4, 2020Assignee: Veltek Associates, Inc.Inventor: Arthur L. Vellutato, Sr.
-
Patent number: 10729796Abstract: A disinfecting unit and method of operating the same includes a cabinet having a vertical axis, a first lamp coupled to the cabinet directing light in a generally radial direction relative to the vertical axis, a second lamp coupled to the cabinet directing light in at least a partially axial direction relative to the vertical axis and a nebulizer that dispenses disinfecting fluid therethrough.Type: GrantFiled: August 3, 2017Date of Patent: August 4, 2020Assignee: E & C Manufacturing, LLCInventor: Stephen J. Paver, Jr.
-
Patent number: 10729797Abstract: UV hard-surface disinfection system that is able to disinfect the hard surfaces in a room, while minimizing missed areas due to shadows by providing multiple UV light towers that can be placed in several areas of a room such that shadowed areas are eliminated and that can be transported by a cart that is low to the ground such that the towers may be loaded and unloaded easily by a single operator. The system is able to be controlled remotely, such that during activation of the system, no operator is present, and to automatically cut power to all towers in the event that a person enters the room.Type: GrantFiled: January 31, 2020Date of Patent: August 4, 2020Assignee: Surfacide, LLCInventors: Waldemar John Lyslo, Mark Howard Schwartz, Stephen Boyd Pettis
-
Patent number: 10729798Abstract: This present invention generally relates to a process for manipulating the chemistry of a product using high voltage atmospheric cold plasma (HVACP) in the presence of a working gas, and in particular to a process for inactivating pathogenic microorganisms in a liquid product by adding an acidic component to or adjusting an acidic component of a product in combination with HVACP treatment. A product of this process is also in the scope of this disclosure.Type: GrantFiled: May 15, 2017Date of Patent: August 4, 2020Assignee: Purdue Research FoundationInventors: Kevin Michael Keener, Nikhil K Mahnot
-
Patent number: 10729799Abstract: An aqueous hydrogen peroxide solution comprises a stabilizer chosen from the family of substituted or unsubstituted aminopolycarboxylic acids (APCA) or salts thereof. The solution may be used for disinfecting a packaging.Type: GrantFiled: November 18, 2016Date of Patent: August 4, 2020Assignee: Arkema FranceInventors: Philippe Zydowicz, Pierre Larnicol
-
Patent number: 10729800Abstract: [Object] It is possible to efficiently perfume using a relatively small amount of fragrance material while an increase in size of a perfuming device is minimized. [Solution] Provided is a cartridge for a perfuming device, including: a main body part; an air flow channel that is provided in the main body part and has both ends that are open; and a fragrance material held in at least a part of an inner surface of the air flow channel.Type: GrantFiled: October 23, 2015Date of Patent: August 4, 2020Assignee: Sony CorporationInventors: Shuji Fujita, Yukari Tsunoda, Tsunetoshi Samukawa, Jusuke Shimura
-
Patent number: 10729801Abstract: Disclosed herein are apparatuses and methods for generating non-thermal plasma which can form reactive oxygen species (ROS), such as those used to neutralize bacteria and other pathogens in the air and surrounding area. Also disclosed are apparatuses and methods for neutralizing bacteria and other pathogens using ROS generated through the use of non-thermal plasma. Also disclosed are apparatuses and methods for generating ROS. Also disclosed are apparatuses and methods for treating air and nearby surfaces.Type: GrantFiled: October 29, 2018Date of Patent: August 4, 2020Assignee: PhoenixAIRE, LLCInventor: Terrance Woodbridge
-
Patent number: 10729802Abstract: The present technology relates to composites, apparatuses, systems, and methods that are based on a photocurable composite useful for stabilizing, supporting, or otherwise healing an injured limb. The photocurable composite includes a light-curable resin and a filler material, where the light-curable resin includes about 50 vol % to about 99 vol % (based on the volume of the light-curable resin) of an acrylate-functionalized oligomer, wherein the backbone of the oligomer comprises a polyurethane, a polyether, a polyester, or a combination of any two or more thereof; about 1 vol % to about 50 vol % of a radical-reactive diluent; about 0.001 vol % to about 2 vol % of a photoinitiator; and optionally about 0.05 to about 25 vol % of a surface cure protection agent.Type: GrantFiled: November 9, 2017Date of Patent: August 4, 2020Assignee: REBOOT MEDICAL INC.Inventors: Joseph Lomakin, Madalyn Berns, Jeff Maynard
-
Patent number: 10729803Abstract: Disposable absorbent articles assembled from a collection of components using an adhesive comprising an amorphous polyolefin composition and a heterophase polyolefin composition comprising amorphous character and crystalline blocks.Type: GrantFiled: April 12, 2019Date of Patent: August 4, 2020Assignee: The Procter & Gamble CompanyInventors: William L. Bunnelle, Robert Haines Turner
-
Patent number: 10729804Abstract: The present invention relates to the use of nanofibrillar cellulose hydrogel in cell culture and medical applications. The invention relates to a composition comprising nanofibrillar cellulose, cross linkable polymer and at least one bioactive agent. The invention also provides methods for producing the composition and uses thereof. The present invention further relates to the use of said composition for manufacturing of a shaped matrix, the method of preparing said matrix, the matrix and the use of said matrix in various applications.Type: GrantFiled: February 10, 2016Date of Patent: August 4, 2020Assignee: UPM-KYMMENE CORPORATIONInventors: Marjo Yliperttula, Patrick Lauren, Petter Somersalo, Yanru Lou
-
Patent number: 10729805Abstract: Described are polymers and methods of forming and using same.Type: GrantFiled: May 3, 2019Date of Patent: August 4, 2020Assignee: Terumo CorporationInventors: Gregory M. Cruise, Xinping Wu, Gloria Hincapie, Yue Wu
-
Patent number: 10729806Abstract: Moisture-curable adhesive compositions, their preparation and use are disclosed herein. The moisture-curable adhesive compositions include one or more reactive polymers, such as reactive silicone polymers, one or more adhesive components, such as a silicone pressure sensitive polymer(s) (PSAs), a cross-linker and a catalyst. Typically, the reactive silicone polymer or polymers are hydroxyl terminated polydimethylsiloxanes (PDMS) having at least two hydroxyl functionalities associated with the polymer(s).Type: GrantFiled: April 28, 2016Date of Patent: August 4, 2020Assignee: Coloplast A/SInventors: Bahar Bingol, Kristoffer Hansen
-
Patent number: 10729807Abstract: Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications.Type: GrantFiled: June 24, 2019Date of Patent: August 4, 2020Assignee: University of Utah Research FoundationInventor: Russell J. Stewart
-
Patent number: 10729808Abstract: The invention relates to a sternum replacement implant.Type: GrantFiled: June 22, 2016Date of Patent: August 4, 2020Assignee: I.CERAMInventors: Daniel Setton, Fabrice Fiorenza, François Bertin, Frank Sturtz, Eric Denes, Delphine Donnez
-
Patent number: 10729809Abstract: Provided herein is a bone repair composition that is composed of periosteum containing an angiogenic growth factor(s), cancellous bone chips containing viable osteogenic cells, and, optionally, demineralized bone matrix (DBM) chips. Also provided herein are articles of manufacture and methods of use thereof to treat bone defects.Type: GrantFiled: September 9, 2015Date of Patent: August 4, 2020Assignee: Osiris Therapeutics, Inc.Inventors: Thomas E. Uveges, Jin-Qiang Kuang, Alla Danilkovitch, S. Michael Sinclair, Sandra D. Geraghty
-
Patent number: 10729810Abstract: The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.Type: GrantFiled: July 18, 2014Date of Patent: August 4, 2020Assignees: CAYMAN CHEMICAL COMPANY, INC, MYOMETRICS LLCInventors: Stephen Douglas Barrett, Joseph Michael Colombo, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Gregory William Endres, Fred Lawrence Ciske, Thomas Allen Owen, James Paul O'Malley
-
Patent number: 10729811Abstract: Methods for inhibiting stenosis, obstruction and/or calcification of a heart valve following implantation in a vessel having a wall are disclosed. In one aspect the method includes providing a bioprosthetic heart valve mounted on an elastical stent; treating the bioprosthetic heart valve with a tissue fixative; coating the stent and the bioprosthetic valve with a coating composition including one or more therapeutic agents; implanting the bioprosthetic valve into the vessel in a diseased natural valve site; eluting the coating composition from the bioprosthetic valve; and inhibiting stenosis, obstruction and/or calcification of the bioprosthetic heart valve by preventing the attachment of stem cells to the bioprosthetic heart valve, the stem cells circulating external and proximate to the bioprosthetic heart valve by activating nitric oxide production (i) in the circulating stem cells, (ii) in an endothelial cell lining covering the bioprosthetic heart valve tissue, (iii) or both.Type: GrantFiled: June 4, 2018Date of Patent: August 4, 2020Assignee: CONCIEVALVE, LLCInventor: Nalini M. Rajamannan
-
Patent number: 10729812Abstract: Methods of producing and methods of treatment using a nipple areolar complex extracellular matrix. A method for processing tissue comprises harvesting a human nipple areolar complex tissue, treating the tissue with a stabilizing medium, wherein the medium stabilizes the tissue during transport, decellularizing the tissue, and sterilizing the tissue to form a human nipple areolar complex extracellular matrix scaffold (ECMS). A method of treating an individual with a need for a nipple reconstruction comprises forming an ECMS and applying the ECMS to the individual for nipple areolar regeneration.Type: GrantFiled: December 9, 2016Date of Patent: August 4, 2020Assignee: NovoThelium, LLCInventors: Bianca G. Cerqueira, Lauren E. Cornell
-
Patent number: 10729813Abstract: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.Type: GrantFiled: October 4, 2019Date of Patent: August 4, 2020Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Stephen F. Badylak, Donald Freytes
-
Patent number: 10729814Abstract: The present disclosure relates to cartilage repair compositions and methods for modifying the proteoglycan content of the compositions. Specifically, the methods relate to serum free, collagen free neocartilage made from chondrocytes that can be used for implants. Proteoglycans, such as aggrecan and sulfated glycosaminoglycan are used and the content modified using temperature changes.Type: GrantFiled: July 30, 2015Date of Patent: August 4, 2020Assignee: Isto Technologies, Inc.Inventors: Neil Kizer, Nicole M. Bergmann, Gary Gage, Huston Davis Adkisson, Michael Maloney
-
Patent number: 10729815Abstract: A combined treatment for nerve injury is provided. Accordingly there is provided a composition comprising a hyaluronic acid, a laminin polypeptide, an antioxidant and an anti-gliotic agent. Also provided are matrices and hydrogels of the composition and methods of using same.Type: GrantFiled: November 29, 2017Date of Patent: August 4, 2020Assignees: Ramot at Tel-Aviv University Ltd., The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterInventors: Shimon Rochkind, Zvi Nevo
-
Patent number: 10729816Abstract: An engineered medical device for treatment of osteonecrosis is provided where the size, porosity and ceramic content of the device can be personalized based on an individual patient's anatomical and physiological condition. The device distinguishes different segments mimicking anatomically-relevant cortical and cancellous segments, in which the cortical segments of the device can sustain mechanical loading, and the cancellous segment of the device can promote bone ingrowth, osteogenesis and angiogenesis.Type: GrantFiled: March 18, 2016Date of Patent: August 4, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Yunzhi Yang, Stuart B. Goodman, Yaser Shanjani
-
Patent number: 10729817Abstract: A medical device, such as a dilatation balloon, including plasticized nylon, and plasticized nylon.Type: GrantFiled: July 17, 2018Date of Patent: August 4, 2020Assignee: Medtronic Vascular, Inc.Inventor: Mingfei Chen
-
Patent number: 10729818Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.Type: GrantFiled: May 5, 2017Date of Patent: August 4, 2020Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
-
Patent number: 10729819Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until implantable device is deployed a an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.Type: GrantFiled: October 15, 2018Date of Patent: August 4, 2020Assignee: Micell Technologies, Inc.Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
-
Patent number: 10729820Abstract: Polymeric coatings, their applications, and the methods of their preparation are described. The coatings may be used to confer desirable properties to the consumer and/or medical products. Also described are methods of loading therapeutic agents on the polymeric coatings and the applications of the drug eluting polymeric coatings thus obtained.Type: GrantFiled: November 13, 2015Date of Patent: August 4, 2020Assignee: Ariste Medical, LLCInventors: Lisa K. Jennings, Jonathan D. McCanless, Xiaoping Chen, Michael Cole
-
Patent number: 10729821Abstract: A method for preparing a chitosan/heparinized graphene oxide composite multilayer film on the surface of a medical magnesium alloy comprises the following steps: firstly preparing negatively charged heparinized graphene oxide; then performing surface chemical treatment and self-assembly of 16-phosphonohexadecanoic acid molecules on the medical magnesium alloy; further covalently immobilizing chitosan on the surface of the magnesium alloy, thereby constructing a positively charged material surface; finally, alternately immersing the surface-modified magnesium alloy material in heparinized graphene oxide and a chitosan solution, and then fully adsorbing, and obtaining the chitosan/heparinized graphene oxide composite multilayer film after drying.Type: GrantFiled: May 27, 2017Date of Patent: August 4, 2020Assignee: HUAIYIN INSTITUTE OF TECHNOLOGYInventors: Changjiang Pan, Tao Liu, Tao Gong, Lincai Zhang, Wei Ye
-
Patent number: 10729822Abstract: Disclosed herein are compositions to use in biofouling-resistant coatings, biofouling-resistant coatings, methods of making biofouling-resistant coatings, biofouling-resistant devices, and methods of making biofouling-resistant devices.Type: GrantFiled: November 30, 2018Date of Patent: August 4, 2020Assignees: The Regents of the University of California, Hydrophilix, Inc.Inventors: Richard B. Kaner, Dayong Chen, Brian T. McVerry, Ethan Rao, Alexandra L. Polasko
-
Patent number: 10729823Abstract: Implantable drug delivery devices include a housing defining a reservoir, a first unit within the reservoir, and a second unit within the reservoir. The first unit contains a drug and the second unit contains a functional agent that facilitates release of the drug. Intravesical drug delivery devices include a housing portion containing a drug formulation and a housing portion containing an excipient, and are configured to release the drug according to a first release profile and the excipient according to a second release profile. Methods include inserting any of these devices into a patient and releasing drug from the device.Type: GrantFiled: August 19, 2014Date of Patent: August 4, 2020Assignee: TARIS Biomedical LLCInventors: Heejin Lee, Karen Daniel, Matthew Sansone
-
Patent number: 10729824Abstract: An implantable biocompatible material includes one or more vacuum deposited layers of biocompatible materials deposited upon a biocompatible base material. At least a top most vacuum deposited layer includes a homogeneous molecular pattern of distribution along the surface thereof and comprises a patterned array of geometric physiologically functional features.Type: GrantFiled: July 31, 2018Date of Patent: August 4, 2020Assignee: Vactronix Scientific, LLC.Inventor: Julio C. Palmaz